1. ALLA AKTIER
  2. NYHETER
  3. ABLIVA

Abliva

Nyheter Abliva Nyheter alla bolag

Abliva AB Interim Report January – September 2022

MARKN.

Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases

Third quarter summary

Important events third quarter (Jul - Sep 2022)

  • Abliva received additional regulatory approvals to start the FALCON study with KL1333.
  • Abliva participated in World Mitochondrial Disease Week 2022 through videos focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases. The videos are available on Abliva’s website.

Financial information

July-September 2022*

  • Net revenues: SEK 31,000 (85,000)
  • Other operating income: SEK 651,000 (0,000)
  • Loss before tax: SEK 25,124,000 (34,854,000)
  • Loss per share before dilution: SEK 0.04 (0.09)
  • Diluted loss per share: SEK 0.04 (0.09)

January-September 2022*

  • Net revenues: SEK 31,000 (103,000)
  • Other operating income: SEK 212,000 (0,000)
  • Loss before tax: SEK 67,688,000 (86,624,000)
  • Loss per share before dilution: SEK 0.11 (0.24)
  • Diluted loss per share: SEK 0.11 (0.24)

* APM Alternative performance measures, see definition on page 20.

The complete Interim report is available for download below and through Abliva's website www.abliva.com.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: https://abliva.com/posts/news-subscription/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Abliva Q3 2022 EN Final

Datum 2022-11-22, kl 08:30
Källa MFN
Bifogade filer
Abliva Q3 2022 EN Final
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!